Skip Navigation


JAC Advance Access originally published online on November 6, 2008
Journal of Antimicrobial Chemotherapy 2009 63(1):146-150; doi:10.1093/jac/dkn451
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
63/1/146    most recent
dkn451v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by D'Angelo, J. G.
Right arrow Articles by Jones-Brando, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Angelo, J. G.
Right arrow Articles by Jones-Brando, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle

John G. D'Angelo1,{dagger},{ddagger}, Claudia Bordón2,{ddagger}, Gary H. Posner1, Robert Yolken2 and Lorraine Jones-Brando2,*

1 Department of Chemistry and The Malaria Research Institute, Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, USA 2 Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA

Received 7 May 2008; returned 14 June 2008; revised 12 August 2008; accepted 2 October 2008


* Corresponding author. Tel: +1-410-614-0730; Fax: +1-410-955-3723; E-mail: lbrando{at}jhmi.edu

Objectives: We sought to improve upon the usefulness of artemisinins as anti-Toxoplasma agents by synthesizing new unsaturated, carba derivatives and then testing them for in vitro efficacy against three steps of the lytic cycle of Toxoplasma gondii tachyzoites.

Methods: Novel derivatives of ART were synthesized and then tested for in vitro antiparasitic activity using T. gondii tachyzoites constitutively expressing β-galactosidase and human fibroblast host cells. Compounds were evaluated for parasite growth inhibition and cytotoxicity, inhibition of replication and inhibition of parasite invasion of host cells.

Results: Five of the seven new derivatives, 3a–c, 3e and 3f, effectively inhibited T. gondii growth (IC50 = 1.0–4.4 µM); however, only three of these proved to be relatively non-cytotoxic (TD50 ≥ 200 µM). The same five derivatives also inhibited tachyzoite replication, and attachment to and invasion of host cells as effectively as or better than the parent compound ART. In addition, one of the derivatives incapable of inhibiting growth, deoxy-3a, was found to inhibit parasite invasion.

Conclusions: These new artemisinin derivatives have the ability to inhibit multiple steps of T. gondii's lytic cycle. Synthetic unsaturated, carba derivatives of ART have potential as therapeutic agents for the prevention and treatment of toxoplasmosis in humans.

Keywords: parasite , toxoplasmosis , treatment , in vitro inhibition , antiparasitic drugs


{dagger} Present address. Division of Chemistry, Alfred University, Meyers Hall 219, Alfred, NY 14802, USA.

{ddagger} These authors contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.